Advances in Synthetic Biology: Twist Bioscience’s New Launches in Viral Controls and High-Throughput Screening
Twist Bioscience Corporation (NASDAQ: TWST), a company renowned for its innovations in synthetic DNA using its proprietary silicon platform, has recently announced two significant advancements designed to meet the growing demands in viral research and high-throughput screening.
Synthetic RNA Control for H5N1 Influenza A
In a move aimed at enhancing scientific research and control efforts related to the H5N1 Influenza A virus, Twist Bioscience has unveiled a synthetic RNA control that covers 99.9% of hemagglutinin (HA) and neuraminidase (NA) genes. H5N1 is one of the viruses causing Highly Pathogenic Avian Influenza (HPAI), commonly known as bird flu, which poses a significant threat to both avian and human populations.
The synthetic RNA control provides a consistent, reliable benchmark for researchers, aiding in the development of diagnostic tests, vaccine efficacy studies, and antiviral drug research. This high-quality control material promises to accelerate progress in comprehending the pathogenic mechanisms, transmission dynamics, and potential treatment options for H5N1 Influenza A.
Twist Multiplexed Gene Fragments (MGFs)
Further expanding its repertoire of synthetic biology solutions, Twist Bioscience introduced Twist Multiplexed Gene Fragments (MGFs). These MGFs consist of pools of directly synthesized double-stranded DNA (dsDNA) fragments, each up to 500 base pairs in length, and uniquely, there is no upper limit on the number of sequences in the pool.
This innovation stands to revolutionize high-throughput screening applications, a critical process in genomics, drug discovery, and synthetic biology. By leveraging Twist Bioscience’s advanced chemical synthesis platform, researchers can produce large libraries of gene fragments quickly and efficiently. The ability to synthesize and screen multiple gene sequences in parallel accelerates the discovery process, allowing for more rapid identification of potential therapeutic targets and genomic studies.
Conclusion
Twist Bioscience’s latest offerings, the synthetic RNA control for H5N1 Influenza A and the Multiplexed Gene Fragments, demonstrate the company’s ongoing commitment to advancing synthetic biology technologies. These products not only address current needs in viral research and high-throughput screening but also pave the way for future breakthroughs in medical and biological sciences. Through their innovative platform, Twist Bioscience continues to empower researchers worldwide, fostering scientific progress and enhancing our understanding of complex biological systems.
Title
Twist Bioscience Unveils Cutting-Edge Tools for Influenza Research and Genomic Screening
Comments